- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05551286
Feasibility of the YATAC Programme (YATAC)
The 'Young Adult Taking Action' Programme for Young Adult Cancer Survivors: a Feasibility Study Evaluating Content and Delivery
Young adult cancer survivors (YACS) aged 18-39 report physical and psychosocial late effects following cancer treatment, impairing quality of life and participation in everyday life. To address such multifactorial challenges complex or multicomponent rehabilitation interventions are needed. Based on this, the 'Young Adult Taking Action' (YATAC) programme was developed to increase participation in everyday life and improve health-related quality of life. The development of the intervention is guided by the British Medical Research Council's guidance (MRC) and the framework for the co-production and prototyping of public health interventions by Hawkins et al.
The present study will investigate the acceptability and fidelity of the intervention at the research clinic of REHPA, the Danish Knowledge Centre for Rehabilitation and Palliative Care in Nyborg, Denmark. A mixed method one-armed feasibility study will be conducted and the results of the study will be used to revise version 1.0 of the programme.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
The Region Of Southern Denmark
-
Nyborg, The Region Of Southern Denmark, Denmark, 5800
- REHPA, the Danish Knowledge Centre for Rehabilitation and Palliative Care
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Being between 18-39 years old at baseline
- Have had any type of cancer
- Have completed primary/active cancer directed treatment (cytotoxic chemotherapy, radiation therapy and/or definitive surgical intervention, while current hormonal treatments or maintenance therapies are permissible)
- Determined a need for rehabilitation determined by the REHPA scale (a linear analogue scale, where the participants indicate how close they are to living the life they desire after ending cancer treatment). The scale ranges from 0= 'goal reached' to 9= 'infinitely far from'
- Have access to a device with Internet options (i.e., smartphone or tablet)
Exclusion Criteria:
- Dependent in basic personal activities of daily living (personal care, dressing and eating)
- No permanent residence in Denmark
- Not able to speak and understand Danish
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Young Adults Taking Action
The programme is person-centered, goal-oriented, and peer-based and is structured around a 5-day residential stay, an online follow-up after five weeks and a 2-day residential follow-up stay after ten weeks.
|
The programme consists of 22 sessions focusing on; 1) everyday life (energy conservation, cognitive challenges, fatigue); 2) Physical activity; 3) psychological issues; 4) work and study d; 5) sexuality and relationship; 7) rights and finance, and 8) goal setting.
The sessions include both education, workshops, and engagement in different activities and will be delivered by a multidisciplinary team.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acceptability; Affective attitude
Time Frame: 10 weeks
|
The participants feelings about the intervention.
Scores between 0-5, with higher scores indicating better feeling.
|
10 weeks
|
|
Fidelity
Time Frame: 10 weeks
|
Defined as the consistency of whether the intervention was implemented as intended.
The professionals register to what extent they have implemented the session as intended on a 5-point Likert scale.
Scores between 0-5, with higher scores indicating higher consistency.
|
10 weeks
|
|
Dose
Time Frame: 10 weeks
|
Defined as the quantity of intervention implemented.
The professionals will report the number of elements implemented and the time used.
In addition, the professional will give information on reasons for deviation from the manual.
|
10 weeks
|
|
Adaptions
Time Frame: 10 weeks
|
Defined as any adjustments made to the intervention.
The professionals register and describe any adaptions they make and the reasons for this.
|
10 weeks
|
|
Acceptability; burden
Time Frame: 10 weeks
|
The participants perceived amount of effort required to participate.
Scores between 0-5, with higher scores indicating high degree of effort.
|
10 weeks
|
|
Acceptability; Ethicality
Time Frame: 10 weeks
|
The participants opinion about the intervention's fit with their individuals value system.
Scores between 0-5, with higher scores indicating higher consistency with value system.
|
10 weeks
|
|
Acceptability; intervention cohesion
Time Frame: 10 weeks
|
The participants understanding of the intervention and how it works.
Scores between 0-5, with higher scores indicating higher understanding of the intervention.
|
10 weeks
|
|
Acceptability; opportunity costs
Time Frame: 10 weeks
|
The participants experience of opportunity costs, like benefits, values, or profits that must be given up to engage in the intervention.
Scores between 0-5, with higher scores indicating higher degree of giving up on opportunity costs, like benefits, values, or profits.
|
10 weeks
|
|
Acceptability; Perceived effectiveness
Time Frame: 10 weeks
|
The participants experience of perceived effectiveness of the intervention.
Scores between 0-5, with higher scores indicating higher degree of perceived effectiveness of the intervention.
|
10 weeks
|
|
Acceptability; Self-efficacy
Time Frame: 10 weeks
|
The participants confidence that they can perform the behavior(s) required to participate in the intervention.
Scores between 0-5, with higher scores indicating higher confidence that they can perform the behavior(s) required to participate in the intervention.
|
10 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Maria Aagesen, PhD student, The University of Southern Denmark
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 1234 (Department of Defense)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterCompletedCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); Atrium Health Wake Forest BaptistRecruitingCancer | Adolescent Cancer | Young Adult CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Palleon Pharmaceuticals, Inc.CompletedMelanoma | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Colon Cancer | Urothelial Cancer | Oncology | CRC | Esophagogastric Junction Cancer | EGJUnited States
-
Yale UniversityNational Institute of Nursing Research (NINR); The Glimpse Group IncRecruitingCancer | Adolescent Cancer | Young Adult CancerUnited States
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
Morehouse School of MedicineRecruiting
Clinical Trials on A rehabilition programme for young adult cancer survivors
-
Duke UniversityNational Cancer Institute (NCI)CompletedMelanoma | Pain | Cancer | Breast Cancer | Fatigue | Psychological Distress | Germ Cell Tumor | Young Adult | Hematologic Cancer | Endocrine CancerUnited States
-
University of AlbertaCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedPediatric Cancer | Sequels | ComplicationsFrance
-
Kaiser PermanenteNational Cancer Institute (NCI)Not yet recruitingSarcoma | Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer | Thyroid Cancer | Testicular Cancer | Melanoma (Skin Cancer) | Colon Rectal Cancer